The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis.
about
Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysisMultikinase Inhibitor-Induced Hand-Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management.Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysisCurrent practices in the management of adverse events associated with targeted therapies for advanced renal cell carcinoma: a national survey of oncologistsTyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanib.Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis.Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review.Increased risk of severe infections in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysisThe risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis.Dermatological adverse events from BRAF inhibitors: a growing problem.Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials.Pazopanib induced hand-foot syndrome.[Hand-foot syndrome with tyrosine kinase inhibitor therapy: treatment recommendations].Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis.Vascular endothelial growth factor (VEGF) antibody significantly increases the risk of hand-foot skin reaction to multikinase inhibitors (MKIs): A systematic literature review and meta-analysis.
P2860
Q27026453-A1F20407-3A7A-4A53-BE0C-E269DBE31A26Q30250106-3CD4BD60-0334-4B7C-ADA3-5AB7A98D3742Q33926377-9E3ECFAB-55A6-4C0F-8B30-885B08666CCBQ34272770-CE61D04F-E589-4559-9091-7C399928EA4DQ35534962-D1230013-B780-47B1-AC93-BC9D74999C02Q35640953-1D1A52C4-DB40-46FA-8D1F-8BF3FEDEDCB1Q35705188-2A064771-1E8F-4069-AA37-A74B9263188AQ36024704-779B3038-9C0A-40BF-A19E-45A6244FF442Q38076349-1258ACC8-10D3-4F88-ADC6-645A47C32720Q38086762-FC776C9E-0897-439C-A203-9AF85ABC7BA4Q38181898-6A19F496-79D6-472B-B3DD-4478786D5DBDQ42085267-541D4C37-BA55-455C-9B0D-D348AFF2D4E4Q44020739-EC0A595E-B791-4426-A365-BA28D706C4ABQ50968798-585EE801-E5A8-434E-80B9-4FF5B4332DBFQ52654231-A77CA20D-0A6A-4E37-942F-1BEAC970C7D4
P2860
The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The risk of hand foot skin rea ...... literature and meta-analysis.
@en
The risk of hand foot skin rea ...... literature and meta-analysis.
@nl
type
label
The risk of hand foot skin rea ...... literature and meta-analysis.
@en
The risk of hand foot skin rea ...... literature and meta-analysis.
@nl
prefLabel
The risk of hand foot skin rea ...... literature and meta-analysis.
@en
The risk of hand foot skin rea ...... literature and meta-analysis.
@nl
P2093
P2860
P1476
The risk of hand foot skin rea ...... f literature and meta-analysis
@en
P2093
Shenhong Wu
Yevgeniy Balagula
P2860
P2888
P304
P356
10.1007/S10637-011-9652-2
P577
2011-03-11T00:00:00Z